Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

43.81 +0.11 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,304,405
Open 43.70
Bid (Size) 43.82 (1)
Ask (Size) 43.83 (16)
Prev. Close 43.70
Today's Range 43.03 - 45.27
52wk Range 27.66 - 118.62
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown
Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows and spreads tight. 
Via Benzinga
Topics Bonds
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
From Vaxcyte, Inc.
Via GlobeNewswire

Performance

YTD
-47.4%
-47.4%
1 Month
+36.2%
+36.2%
3 Month
+20.4%
+20.4%
6 Month
+36.7%
+36.7%
1 Year
-61.3%
-61.3%

More News

Read More
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
Via Benzinga
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
From Vaxcyte, Inc.
Via GlobeNewswire
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Vaxcyte (PCVX) Q2 Loss Widens 11%
Via The Motley Fool
Topics Intellectual Property
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Top stock movements in today's session.
Via Chartmill
Monday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Monday's pre-market session: top gainers and losers
Via Chartmill
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Via Investor's Business Daily
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
From Vaxcyte, Inc.
Via GlobeNewswire
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Are Small-Cap Stocks A Buy After Russell 2000 Correction?
Via Benzinga
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?
Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
What exchange does Vaxcyte, Inc. - Common Stock trade on?
Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
What is the current price of Vaxcyte, Inc. - Common Stock?
The current price of Vaxcyte, Inc. - Common Stock is 43.81
When was Vaxcyte, Inc. - Common Stock last traded?
The last trade of Vaxcyte, Inc. - Common Stock was at 10/13/25 04:00 PM ET
What is the market capitalization of Vaxcyte, Inc. - Common Stock?
The market capitalization of Vaxcyte, Inc. - Common Stock is 4.11B
How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
Vaxcyte, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.